How Center Volumes Affect Early Outcomes in Acute Myeloid Leukemia

Hospital volume and acute myeloid leukemia mortality in Medicare beneficiaries aged 65 years and older

“…[5][6][7] As is the case in complex and invasive procedures, [8][9][10][11][12] effective management of AML in older patients may require health professionals with specialized skills and resources, which are more likely to be present in hospitals treating these patients more frequently. 13,14 Therefore, the purpose of this study was to better understand the volume-outcome relationship in AML.…”

What Is the Best Choice and Dose of Anthracycline for Induction Chemotherapy in Acute Myeloid Leukemia?

“…Consequentially, normal hematopoiesis is inhibited, resulting in neutropenia, anemia and thrombocytopenia. Patients usually present with signs and symptoms of underlying bone marrow failure including fatigue, lethargy, shortness of breath, bruising, bleeding and infections [1][2][3].…”

“…It is primarily a disease of the elderly with the median age at diagnosis being 68 years and accounts for 80-90% of all acute leukemias in adults. There are approximately 20,000 new cases of AML diagnosed every year in the United States, accompanied by nearly 10,000 deaths [1,3,4].…”

Observation Versus Immediate Reinduction for Acute Myeloid Leukemia Patients With Indeterminate Day 14 Bone Marrow Results

“…4 The goal of the induction phase is to achieve complete remission (CR) and proceed to consolidation therapy with either high doses of cytarabine or allogeneic hematopoietic stem cell transplantation (HSCT) according to the underlying karyotype and molecular aberrations. 5,6 Of the patients with newly diagnosed AML, 10% to 40% will not achieve CR after anthracycline-containing induction therapy. 7,8 In the United States, the initial response to induction therapy has been commonly assessed with a bone marrow evaluation performed on day 14.…”